Clinical Trials
54 trialsA Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
RemeGen Co., Ltd.
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
RemeGen Co., Ltd.
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
RemeGen Co., Ltd.
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Pediatric_PK
Nabriva Therapeutics AG
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
BC3195
Biocity Biopharmaceutics Co., Ltd.
Clinical Trial Evaluating the Safety of the TQB2103 for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Henlius Biotech
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc.
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009
Bio-Thera Solutions
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor
Beijing Nuokangda Pharmaceutical Technology Co., Ltd.
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
Henlix, Inc
A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients
Bio-Thera Solutions
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Bio-Thera Solutions